Institute of Neuropathology, University Medical Center, Göttingen, Germany.
Department of Neurosciences, Centre de recherche de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.
Brain. 2019 Sep 1;142(9):2737-2755. doi: 10.1093/brain/awz190.
Poor vitamin D status is associated with a higher relapse rate and earlier disability in multiple sclerosis. Based on these associations, patients with multiple sclerosis are frequently supplemented with the vitamin D precursor cholecalciferol, although it is unclear whether this regimen is of therapeutic benefit. To model consequences of this common practice, mice were fed for more than 3 months with a low, medium or high dose of cholecalciferol, representative of vitamin D deficiency, modest and disproportionally high supplementation, respectively, in patients with multiple sclerosis. Compared to vitamin D-deprived mice, its moderate supplementation reduced the severity of subsequent experimental autoimmune encephalomyelitis, which was associated with an expansion of regulatory T cells. Direct exposure of murine or human T cells to vitamin D metabolites inhibited their activation. In contrast, mice with 25-(OH) vitamin D levels above 200 nmol/l developed fulminant experimental autoimmune encephalomyelitis with massive CNS infiltration of activated myeloid cells, Th1 and Th17 cells. When dissecting this unexpected outcome, we observed that high, but not medium dose vitamin D had caused mild hypercalcaemia, which rendered T cells more prone to pro-inflammatory activation. Exposing murine or human T cells to equivalent calcium concentrations in vitro enhanced its influx, triggering activation, upregulation of pro-inflammatory gene products and enhanced transmigration across a blood-brain barrier model. These findings suggest that vitamin D at moderate levels may exert a direct regulatory effect, while continuous high dose vitamin D treatment could trigger multiple sclerosis disease activity by raising mean levels of T-cell excitatory calcium.
维生素 D 状态不佳与多发性硬化症的更高复发率和更早残疾有关。基于这些关联,多发性硬化症患者经常补充维生素 D 前体胆钙化醇,尽管尚不清楚这种治疗方案是否具有治疗益处。为了模拟这种常见做法的后果,研究人员用低、中、高剂量的胆钙化醇喂养小鼠超过 3 个月,分别代表维生素 D 缺乏、适度和不成比例的高补充,这分别代表多发性硬化症患者的情况。与维生素 D 缺乏的小鼠相比,其适度补充可降低随后实验性自身免疫性脑脊髓炎的严重程度,这与调节性 T 细胞的扩增有关。鼠或人 T 细胞直接暴露于维生素 D 代谢物会抑制其激活。相比之下,25-(OH)维生素 D 水平高于 200 nmol/L 的小鼠会发展出暴发性实验性自身免疫性脑脊髓炎,伴有大量激活的髓样细胞、Th1 和 Th17 细胞在中枢神经系统中的浸润。当剖析这种意外结果时,我们观察到高剂量但不是中剂量的维生素 D 会导致轻度高钙血症,这使 T 细胞更容易发生促炎激活。体外将鼠或人 T 细胞暴露于等效的钙浓度会增强其流入,触发激活、上调促炎基因产物并增强穿过血脑屏障模型的迁移。这些发现表明,适度水平的维生素 D 可能会发挥直接调节作用,而持续高剂量的维生素 D 治疗可能会通过提高 T 细胞兴奋性钙的平均水平引发多发性硬化症的疾病活动。